Eli Lilly Australia has confirmed that its diabetes medicine MOUNJARO (tirzepatide) will not be listed on the Pharmaceutical Benefits Scheme for type 2 diabetes, despite receiving a positive recommendation from the Pharmaceutical Benefits Advisory Committee. …
Lilly's Mounjaro will not be listed on PBS because of 'unrealistic' recommendation
April 28, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 8 May 2026
May 8, 2026 - - Podcast -
Victoria joins state-funded MenB programs as PBAC rejection creates another 'postcode lottery'
May 8, 2026 - - Latest News -
The approaching major change in Australia’s PBS wholesaling arrangements
May 8, 2026 - - Latest News -
Lilly marks 150 years by lighting a new horizon for health at Vivid Sydney
May 8, 2026 - - Latest News -
Stakeholders must act to protect their voice in response to the risk of a manufactured consensus
May 7, 2026 - - Latest News -
Moderna expands support for early career Australian mRNA researchers
May 7, 2026 - - Latest News -
The review is formally over. Why is it restarting?
May 7, 2026 - - Latest News